{"slug":"alnylam-pharmaceuticals","name":"앨라일람","name_en":"Alnylam Pharmaceuticals","ticker":"ALNY","updated_at":"2026-07-11T10:15:11.892+00:00","canonical":"https://valuechain.wiki/alnylam-pharmaceuticals","kicker":"헬스케어 · NASDAQ 100","kicker_en":"Health Care · NASDAQ 100","lead":"RNA 간섭(RNAi) 기술로 희귀 유전질환 치료제를 개발하는 바이오 기업이다. NASDAQ 100 구성종목. 섹터: 헬스케어(Biotechnology). 밸류체인 관계·수치 데이터는 조사 전인 기본 노드로, AI 질문 수요가 관측되면 상세 노드로 승격된다.","lead_en":"A biotech developing RNA interference (RNAi) therapies for rare genetic diseases. NASDAQ 100 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.","segments":{"parts":[{"name":"RNAi 치료제 제품"},{"name":"협업·로열티"}],"total":"약 $2.25B (FY2024)"},"segments_en":{"parts":[{"name":"RNAi Product Sales"},{"name":"Collaboration & Royalties"}],"total":"~$2.25B (FY2024)"},"returns_yearly":{"2021":30.5,"2022":40.1,"2023":-19.5,"2024":22.9,"2025":69,"2026":-24.9},"return_asof":"2026-07-10","value_chain":{"leading":[],"benefiting":[],"analysis":null,"analysis_en":null,"analysis_asof":null},"edges":[]}